Related Experiment Videos
Hematopoietic stem cell transplantation and cellular therapy.
H-J Kolb1,2,3,4
1Helmholtz Zentrum Muenchen, Muenchen, Germany.
HLA
|April 4, 2017
Summary
Allogeneic stem cell transplants improve survival for leukemia patients but face challenges like graft-vs-host disease (GVHD). Strategies are explored to enhance the graft-vs-leukemia (GVL) effect while minimizing GVHD for better outcomes.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Allogeneic stem cell transplantation (allo-SCT) offers a survival advantage for patients with relapsed or high-risk leukemia.
- Graft-vs-host disease (GVHD) and infections are significant complications following allo-SCT.
- T-cell depletion, a strategy to prevent GVHD, can lead to graft rejection, delayed immune reconstitution, and increased relapse rates.
Purpose of the Study:
- To review factors influencing GVHD in allo-SCT.
- To explore strategies for separating the graft-vs-leukemia (GVL) effect from GVHD.
- To discuss the role of cellular therapies in improving allo-SCT outcomes.
Main Methods:
- Review of current literature on GVHD prophylaxis and GVL enhancement.
- Analysis of advances in histocompatibility, chimerism, and tolerance.
- Evaluation of cellular therapies, including donor lymphocyte infusions (DLI).
Main Results:
- GVHD remains a major challenge in allo-SCT, impacting vital organs.
- T-cell depletion strategies for GVHD prophylaxis have drawbacks, including increased relapse risk.
- Separating GVL from GVHD is crucial for optimizing allo-SCT efficacy.
Conclusions:
- Further research into histocompatibility, chimerism, and tolerance is needed to foster GVL over GVHD.
- Cellular therapies, such as DLI, show promise for disease control post-transplant.
- Optimizing allo-SCT requires balancing the benefits of immune-mediated anti-leukemia effects with the risks of GVHD.